• Thurs news: Novartis buys Kate Therapeutics. Trump’s likely FDA pick. Bayer tries for new Nubeqa indications. New CSO for Amgen. Versant developing new type of obesity drug. See more on our front page

Layoffs 100%

Quote












anonymous said:
Market Access before Sales Force.
Click to expand...
It’s called Value and Access dumbass. You should be one of the 1st to go.

That said, there has already been some blood letting from the V&A team. Let’s be honest. The whole health system plan has done little to nothing. Big sales force with little return. There are sole good KAMS but what do they really do? We should combine them with the SAR team and then cut them in 1/2. No need for all the headcount or the overpaid CBD’s who are only looking for a shot to write a contract with a system. Hint…ain’t gonna happen no matter how many exploratory meetings you have. The V&A team doesn’t have that level of data capture or infrastructure. And gross to net is rough enough. Do you think anyone responsible wants to eat into our net sales any deeper? The company is looking for ways to SAVE money, not spend more.

As for V&A, you can eliminate some of the directors and higher. Too many of them and no clarity on what they actually do. Plus, they’re all pulling in well over $240,000+ with a decent VPR % target.
 




anonymous said:
It’s called Value and Access dumbass. You should be one of the 1st to go.

That said, there has already been some blood letting from the V&A team. Let’s be honest. The whole health system plan has done little to nothing. Big sales force with little return. There are sole good KAMS but what do they really do? We should combine them with the SAR team and then cut them in 1/2. No need for all the headcount or the overpaid CBD’s who are only looking for a shot to write a contract with a system. Hint…ain’t gonna happen no matter how many exploratory meetings you have. The V&A team doesn’t have that level of data capture or infrastructure. And gross to net is rough enough. Do you think anyone responsible wants to eat into our net sales any deeper? The company is looking for ways to SAVE money, not spend more.

As for V&A, you can eliminate some of the directors and higher. Too many of them and no clarity on what they actually do. Plus, they’re all pulling in well over $240,000+ with a decent VPR % target.
Click to expand...
They are called SAEs dumbass and CBDs don’t contract with systems.
 








anonymous said:
They are called SAEs dumbass and CBDs don’t contract with systems.
Click to expand...
It was a typo you cocksucker. Letter ‘R’ is right next to letter ‘E’. I have fat fingers that would make you salivate and your bung hole sweat.

CBD’s are always looking for opportunities to contract. Most of them think a ‘contract’ will make them a better CBD on their MAG plan. No consideration for the ability to actually manage the contract and whether or not it will be a good business decision for the organization.
 




























Better prep for the delousing. Global is not happy with results. It’s one thing is one of the smaller Asian or Euro countries performs poorly. But, when the US fumbles, the shit hits the fan.

Expect major cost cutting. And the big cost savings….trim the overhead fat.
 




BI might be competing with the NY Football Giants for a top draft pick. I think the Giants may be a little bit worse, but it’s still a close race.

Giants have Daniel Jones who can’t through a TD to save his life.

BI can’t sell a biosimilar to save themselves.
 




anonymous said:
BI might be competing with the NY Football Giants for a top draft pick. I think the Giants may be a little bit worse, but it’s still a close race.

Giants have Daniel Jones who can’t through a TD to save his life.

BI can’t sell a biosimilar to save themselves.
Click to expand...
Any idiot who likes the Giants or Jets needs their head examined. They are like BI of the NFL. They have some mediocre players and even worse coaching and ownership. I’d rather watch a 4 hour town hall hosted by YL than either of those teams.

Jets and Giants fans can be the placebo group for Iclepertin and CT155 studies.
 




anonymous said:
BI might be competing with the NY Football Giants for a top draft pick. I think the Giants may be a little bit worse, but it’s still a close race.

Giants have Daniel Jones who can’t through a TD to save his life.

BI can’t sell a biosimilar to save themselves.
Click to expand...
Through? Go back to school to learn how to spell throw and then come back and add your two cents. What an idot! I mean idiot- just trying to make you feel better and let you know it wasn’t a spell correct issue…
 




anonymous said:
Through? Go back to school to learn how to spell throw and then come back and add your two cents. What an idot! I mean idiot- just trying to make you feel better and let you know it wasn’t a spell correct issue…
Click to expand...
Regardless (or irregardless??) of how you spell it, the poster was right that the a
giants and jets are an embarrassment to the NFL. Similar to how BI is an embarrassment to pharma.

The VPR news is causing many to update their resumés and get them out to recruiters. Can’t wait to see all the ‘I’m looking’ LinkedIn borders on profiles.

Better find something quickly before the PTO policy change.
 












Top Bottom
Back
Quote